178 related articles for article (PubMed ID: 3496637)
21. The role of MAO in MPTP toxicity--a review.
Glover V; Gibb C; Sandler M
J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
[TBL] [Abstract][Full Text] [Related]
22. Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
Pretorius A; Ogunrombi MO; Fourie H; Terre'blanche G; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2010 Jun; 18(11):4111-8. PubMed ID: 20451395
[TBL] [Abstract][Full Text] [Related]
23. Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mabic S; Castagnoli N
J Med Chem; 1996 Sep; 39(19):3694-700. PubMed ID: 8809158
[TBL] [Abstract][Full Text] [Related]
24. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK; Perry KW
J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
[TBL] [Abstract][Full Text] [Related]
25. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].
Unger EL; Mazzola-Pomietto P; Murphy DL; Andrews AM
J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632
[TBL] [Abstract][Full Text] [Related]
26. Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
J Neurochem; 1985 Oct; 45(4):1049-54. PubMed ID: 3928814
[TBL] [Abstract][Full Text] [Related]
27. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Youngster SK; Sonsalla PK; Heikkila RE
J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
[TBL] [Abstract][Full Text] [Related]
29. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
30. Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone.
Yoshihara S; Ohta S
Arch Biochem Biophys; 1998 Dec; 360(1):93-8. PubMed ID: 9826433
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Rajeswari A; Sabesan M
Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
[TBL] [Abstract][Full Text] [Related]
32. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.
Luellen BA; Miller DB; Chisnell AC; Murphy DL; O'Callaghan JP; Andrews AM
J Pharmacol Exp Ther; 2003 Dec; 307(3):923-31. PubMed ID: 14561848
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.
Kindt MV; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1987 Sep; 242(3):858-63. PubMed ID: 3498818
[TBL] [Abstract][Full Text] [Related]
34. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
35. Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Fuller RW; Hahn RA; Snoddy HD; Wikel JH
Biochem Pharmacol; 1984 Oct; 33(19):2957-60. PubMed ID: 6333240
[TBL] [Abstract][Full Text] [Related]
36. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals.
Donnan GA; Kaczmarczyk SJ; Solopotias T; Rowe P; Kalnins RM; Vajda FJ; Mendelsohn FA
Clin Exp Neurol; 1986; 22():155-64. PubMed ID: 3495376
[TBL] [Abstract][Full Text] [Related]
37. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
[TBL] [Abstract][Full Text] [Related]
38. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
39. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in preparations of rat brain.
Markstein R; Lahaye D
Eur J Pharmacol; 1984 Nov; 106(2):301-11. PubMed ID: 6335691
[TBL] [Abstract][Full Text] [Related]
40. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
J Pharmacol Exp Ther; 1986 Aug; 238(2):648-52. PubMed ID: 3488394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
